Association of HLA-DQB1 alleles with interferon/ribavirin therapy outcomes in a Romanian patient group infected with hepatitis C virus genotype 1b

Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals

“…We identified a significant inverse correlation between the duration of HCV infection and the quantitative decrease in liver stiffness, r s =-0.326, p=0.017, N=53, but this association was not statistically significant when comparing the qualitative regression in liver fibrosis, despite the fact that patients who achieved a one stage decrease in fibrosis had a slightly lower median (IQR) duration of HCV infection, 12 (7)(8)(9)(10)(11)(12)(13)(14)(15)(16) years, compared with those who did not achieve regression of liver fibrosis, 13.5 (9-16) years (U=320.5, p=0.578, r=0.08).…”

“…We also assessed whether there is an association between the regression of liver fibrosis with classical prognostic factors previously used for calculating the chance of obtaining SVR following interferon-based treatment, such as: younger age (7,8), female gender (9), IL28B CC rs12979860 (10) or other genetic polymorphisms (11,12), baseline viral load below 600,000 IU/mL (13,14), absence of diabetes mellitus (15), shorter duration of HCV infection (16) calculated as the time (years) since the first positive anti-HCV test, and absence of surrogate markers for advanced liver disease at baseline.…”

HLA-DQB1*0301 in Bullous Pemphigoid and Pemphigus Vulgaris: A Meta-Analysis

“…HLA-DQB1*0301 is one specific allele with implications to care, as it is connected to prognosis, treatment response, and even symptom profile in dermatologic conditions. [8][9][10] This is apparent with BP and PV, which are also seemingly connected to the allele. [10][11] With this allele being mentioned in both skin conditions as showing opposing effects of protecting versus predisposing patients to PV and BP, a meta-analysis is necessary.…”